- Trials with a EudraCT protocol (12)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
12 result(s) found for: Loss of libido.
Displaying page 1 of 1.
EudraCT Number: 2009-010549-30 | Sponsor Protocol Number: 44/09 | Start Date*: 2009-12-16 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: PRAMIPEXOLE IN THE MALE LIBIDO FAILURE : A PHASE II, off-label, pilot study | |||||||||||||
Medical condition: male libido failure | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002770-23 | Sponsor Protocol Number: EB91 | Start Date*: 2011-07-04 | ||||||||||||||||||||||||||
Sponsor Name:Emotional Brain BV | ||||||||||||||||||||||||||||
Full Title: A double-blind, randomized, placebo-controlled, proof of concept study to investigate the safety and efficacy of the combined administration of 0.5 mg sublingual testosterone and 10 mg tadalafil in... | ||||||||||||||||||||||||||||
Medical condition: Hypoactive Sexual Desire Disorder | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019285-86 | Sponsor Protocol Number: EB79 | Start Date*: 2010-05-07 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Emotional Brain | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A single blind, randomized, cross-over placebo controlled dose finding study to investigate the pharmacokinetic profile of 3 doses of sublingual testosterone solution and their effect on physiologi... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: This pharmacokinetic trial will be conducted in healthy women, but it is a part of a developmental program for medicine for Hypoactive Sexual Desire Disorder (comorbidity with other sexual dysfunct... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003543-30 | Sponsor Protocol Number: EB93 | Start Date*: 2012-08-24 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Emotional Brain BV | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A double-blind, randomized, placebo-controlled, proof of concept study to investigate the differences between the combined administration of 0.5 mg sublingual testosterone and 10 mg buspirone and 1... | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Hypoactive Sexual Desire Disorder Sexual Interest/Arousal Disorder | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019540-39 | Sponsor Protocol Number: EB80 | Start Date*: 2010-05-12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Emotional Brain | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A double blind, randomized, cross-over placebo controlled study to investigate the efficacy of sublingual testosterone solution on physiological and subjective arousal in healthy, sexually dysfunct... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: This pharmacodynamic trial will be conducted in sexually dysfunctional otherwise healthy women, but it is a part of a developmental program for medicine for Hypoactive Sexual Desire Disorder (comor... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001998-15 | Sponsor Protocol Number: TRIB–01–08 | Start Date*: 2010-08-30 | ||||||||||||||||
Sponsor Name:SOPHARMA PLC | ||||||||||||||||||
Full Title: A phase IV, 16 weeks, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to assess the efficacy and safety of oral Tribulus terrestris (Tribestan®) in men with erectile dysfun... | ||||||||||||||||||
Medical condition: This Phase IV, 16 weeks study will be multicenter, randomized, double-blind, placebo-controlled. It will evaluate the efficacy and safety of Tribestan compared to placebo in men with erectile dysfu... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male | |||||||||||||||||
Trial protocol: BG (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-000866-41 | Sponsor Protocol Number: 2019001_mife50 | Start Date*: 2021-02-02 |
Sponsor Name:Women on Web International Foundation | ||
Full Title: Combined Phase II/ III Multicentre Single-arm Trial of a Mifepristone 50 mg as a weekly Contraceptive | ||
Medical condition: Prevention of unwanted pregnancy | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: (No results available) |
EudraCT Number: 2020-002355-38 | Sponsor Protocol Number: mife50 | Start Date*: 2021-11-29 |
Sponsor Name:women on web international foundation | ||
Full Title: Prospective multi-center single arm open label study of efficacy, safety and acceptability of long-term weekly oral Mifepristone 50 mg as contraceptive | ||
Medical condition: prevent pregnancy | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: (No results available) |
EudraCT Number: 2005-002607-17 | Sponsor Protocol Number: TSX/01/C | Start Date*: 2005-11-18 |
Sponsor Name:Prostrakan Pharmaceuticals Ltd | ||
Full Title: Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus | ||
Medical condition: Male hypogonadism is generally characterised by abnormally low serum testosterone levels. Symptoms include changes in mood, decreased bone mineral density, increased body fat, decreased muscle mass... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (Completed) DE (Completed) BE (Completed) ES (Completed) SE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-001222-25 | Sponsor Protocol Number: 2004031 | Start Date*: 2004-10-05 | |||||||||||
Sponsor Name:Procter and Gamble Pharmaceuticals | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, 52-week Study to Evaluate the Efficacy ans Safety of Transdermal Patches Delivering 150 or 300 microgram/day Testosteron... | |||||||||||||
Medical condition: Hypoactive sexual desire disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000256-33 | Sponsor Protocol Number: Ra-P-OCD-01 | Start Date*: 2019-06-27 | |||||||||||
Sponsor Name:Uppsala University Hospital | |||||||||||||
Full Title: A randomized, double-blinded, placebo-controlled study of Rituximab in patients with Psychosis and/or Obsessive Compulsive Disorder, with an indication of immune system involvement | |||||||||||||
Medical condition: Obsessive-compulsive disorder (OCD) or Obsessive-compulsive behaviour (OCB) or psychotic disorder (PD) in which there is an indication of immune system involvement. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003063-26 | Sponsor Protocol Number: 1634 | Start Date*: 2023-08-10 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC) | |||||||||||||
Full Title: Personalized Risk-Adapted Therapy in Post-Pubertal Patients with Newly Diagnosed Medulloblastoma (PersoMed-I) | |||||||||||||
Medical condition: Newly Diagnosed Medulloblastoma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) DE (Trial now transitioned) IT (Prematurely Ended) FR (Prematurely Ended) NL (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
